You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱景生物(688068.SH)2019年度淨利潤降29.63%至3387.78萬元 擬10派3元
格隆匯 04-22 18:54

格隆匯4月22日丨熱景生物(688068.SH)發佈2019年年度報告,實現營業收入2.10億元,同比增長12.45%;歸屬於母公司所有者的淨利潤3387.78萬元,同比減少29.63%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2691.73萬元,同比下降28.23%;基本每股收益0.67元,擬每10股派發現金紅利3元(含税)。

公司是一家從事研發、生產和銷售體外診斷試劑及儀器的生物高新技術企業,以發展生物科技,造福人類健康為使命,秉承檢驗因我而先進的理念,持續聚焦醫學與公共安全檢測領域產品的創新與產業化。公司的主要產品為體外診斷試劑及儀器,主要應用於肝癌肝炎、心腦血管疾病、炎症感染等臨牀領域和生物安全、食品安全、疾控應急等公共安全及其他領域。按照檢測方法分類,公司主要產品屬於免疫診斷類別。

熱景生物經過持續多年技術研發,構建了以上轉發光技術、磁微粒化學發光技術、糖捕獲技術、基因重組與單克隆抗體技術為核心的研發技術平台,開發了一系列的體外診斷試劑及儀器,可應用於全場景的免疫診斷。其中上轉發光技術率先將稀土元素所構成的上轉發光材料(UCP)應用於臨牀及生物安全領域,並榮獲2015年國家技術發明二等獎,是目前國內唯一獲得此獎項的免疫診斷方法學。磁微粒化學發光作為免疫診斷的國際主流先進技術,公司通過持續多年研發投入,掌握了單人份化學發光和高通量化學發光技術,連續開發出小型、中型、大型全自動化學發光儀器和試劑產品,構建起可滿足不同終端用户需求的全場景(POCT現場快速檢測、中心實驗室自動化高通量檢測)免疫診斷平台,成為業內為數不多的產品涵蓋全場景應用的供應商之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account